Edition:
United States

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

33.16USD
16 Feb 2018
Change (% chg)

$0.82 (+2.54%)
Prev Close
$32.34
Open
$32.25
Day's High
$33.23
Day's Low
$31.71
Volume
666,027
Avg. Vol
436,630
52-wk High
$55.94
52-wk Low
$24.45

Latest Key Developments (Source: Significant Developments)

State Street Global Advisors Announces Impact Of Receiving Settlement Payment
Friday, 5 Jan 2018 05:12pm EST 

Jan 5 (Reuters) - State Street Corp ::STATE STREET GLOBAL ADVISORS ANNOUNCES IMPACT OF RECEIVING SETTLEMENT PAYMENT.SPDR EXCHANGE TRADED FUND - RECEIVED PAYMENT AS AUTHORIZED CLAIMANT FROM A CLASS ACTION SETTLEMENT RELATED TO MEDICINES COMPANY​.  Full Article

Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company
Wednesday, 29 Nov 2017 07:00am EST 

Nov 29 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY.  Full Article

Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics
Wednesday, 29 Nov 2017 07:00am EST 

Nov 29 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS.MEDICINES - TO SELL INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS FOR $270 MILLION IN UPFRONT CONSIDERATION AND GUARANTEED PAYMENTS.MEDICINES - DEAL INCLUDES TIERED ROYALTY PAYMENTS OF 5% TO 25% ON WORLDWIDE NET SALES OF VABOMERE, ORBACTIV AND MINOCIN IV, AMONG OTHER THINGS.MEDICINES CO - MELINTA TO PAY DEAL CONSIDERATION, INCLUDING $165 MILLION IN CASH, PAID AT CLOSING, MELINTA SHARES WITH A MARKET OF $55 MILLION, AMONG OTHERS.MEDICINES CO - ‍CONCURRENT WITH EXECUTION OF DEAL, CO RECEIVED BINDING COMMITMENT FROM DEERFIELD MANAGEMENT AFFILIATE.MEDICINES CO - DEERFIELD MANAGEMENT ‍AFFILIATE COMMITTED TO PROVIDE FINANCING TO MELINTA IN CONNECTION WITH DEAL,TO PROVIDE A $100 MILLION CREDIT FACILITY​.  Full Article

Medicines Co names Fred Eshelman executive chairman
Wednesday, 15 Nov 2017 07:30am EST 

Nov 15 (Reuters) - Medicines Co -:The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors.Medicines Co - ‍appointed FREDRIC N. ESHELMAN, company's current chairman of board, to newly created position of executive chairman​.Medicines Co - ‍appointments are effective immediately​.  Full Article

SymBio Pharmaceuticals says arbitration against The Medicines Company
Monday, 13 Nov 2017 01:50am EST 

Nov 13 (Reuters) - SymBio Pharmaceuticals Ltd <4582.T>:Says co initiated an arbitration against The Medicines Company (MDCO) on Oct. 11, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement entered into between the co and MDCO on October 5, 2015, for the exclusive rights to develop and commercialize the patient-controlled pain management drug "SyB P-1501" (or "IONSYS") in Japan.Says the co seeks damages of $82 million (about 9 billion yen).  Full Article

The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Medicines Co :The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran.Medicines Co - ‍continues to expect that all of these trials will commence before end of 2017​.  Full Article

The Medicines Company reports third-quarter 2017 business and financial results
Wednesday, 25 Oct 2017 07:00am EDT 

Oct 25 (Reuters) - Medicines Co :The Medicines Company reports third-quarter 2017 business and financial results.Q3 GAAP loss per share $0.42 from continuing operations.Q3 earnings per share view $-1.44 -- Thomson Reuters I/B/E/S.Q3 adjusted non-GAAP loss per share $1.19 from continuing operations.Says ‍operations worldwide net revenue was $16.9 million in Q3 of 2017 compared to $37.6 million in Q3 of 2016​.Medicines Co - ‍continue to expect to announce a transaction to divest infectious disease business before end of year.Medicines Co - ‍independent of ID business transaction, finalizing plans to significantly restructure remainder of Medicines Company​.Medicines Co - ‍anticipate restructuring, intended to be substantially implemented in next 45 days, will reduce headcount to less than 60 people at Co.Q3 revenue view $24.4 million -- Thomson Reuters I/B/E/S.  Full Article

The Medicines Company announces FDA approval of Vabomere
Wednesday, 30 Aug 2017 07:00am EDT 

Aug 30 (Reuters) - Medicines Co :The Medicines Company announces FDA approval of Vabomere (meropenem and vaborbactam).Vabomere expected to be available in Q4 of 2017.  Full Article

Alnylam says ‍inclisiran phase III development program gearing up​
Monday, 28 Aug 2017 07:00am EDT 

Aug 28 (Reuters) - Alnylam Pharmaceuticals Inc :New, one-year data from orion-1 phase ii study of inclisiran extends excellent long-term efficacy and safety profile, affirming dose for phase iii trials.Alnylam pharmaceuticals inc - ‍inclisiran phase iii development program gearing up​.  Full Article

Medicines Co reports Q2 GAAP loss per share $5.52 from continuing operations
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Medicines Co :The Medicines Company reports second quarter 2017 business and financial results.Q2 GAAP loss per share $5.52 from continuing operations.Q2 revenue $18.7 million versus $54.7 million.Q2 earnings per share view $-1.96 -- Thomson Reuters I/B/E/S.Q2 revenue view $28.4 million -- Thomson Reuters I/B/E/S.Q2 adjusted non-GAAP loss per share $1.02 from continuing operations.  Full Article

BRIEF-Medicines Co Reports 10.6 Pct Passive Stake In Melinta Therapeutics

* THE MEDICINES COMPANY REPORTS 10.6 PERCENT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN. 5, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2muRQBT) Further company coverage: